The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Renin-Angiotensin-Aldosterone System and Progression of Renal Disease
Abstract
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is one of the most powerful maneuvers to slow progression of renal disease. Angiotensin II (AngII) has emerged in the past decade as a multifunctional cytokine that exhibits many nonhemodynamic properties, such as acting as a growth factor and profibrogenic cytokine, and even having proinflammatory properties. Many of these deleterious functions are mediated by other factors, such as TGF-beta and chemoattractants that are induced in the kidney by AngII. Moreover, understanding of the RAAS has become much more complex in recent years with the identification of novel peptides (e.g., AngIV) that could bind to specific receptors, elucidating deleterious effects, and non-angiotensin-converting enzyme (ACE)-mediated generation of AngII. The ability of renal cells to produce AngII in a concentration that is much higher than what is found in the systemic circulation and the observation that aldosterone may be engaged directly in profibrogenic processes independent of hypertension have added to the complexity of the RAAS. Even renin has now been identified to have a "life on its own" and mediates profibrotic effects via binding to specific receptors. Finally, drugs that are used to block the RAAS, such as ACE inhibitors or certain AngII type 1 receptor antagonists, may have properties on cells independent of AngII (ACE inhibitor-mediated outside-inside signaling and peroxisome proliferator-activated receptor-gamma stimulatory effects of certain sartanes). Although blockade of the RAAS with ACE inhibitors, AngII type 1 receptor antagonists, or the combination of both should be part of every strategy to slow progression of renal disease, a better understanding of the novel aspects of the RAAS should contribute to the development of innovative strategies not only to completely halt progression but also to induce regression of human renal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
Dragun, D., Müller, D. N., Bräsen, J. H., Fritsche, L., Nieminen-Kelhä, M., Dechend, R., Kintscher, U., Rudolph, B., Hoebeke, J., Eckert, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa035717 · Cited by 868
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
Remuzzi, G. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27699 · Cited by 618
From the Periphery of the Glomerular Capillary Wall Toward the Center of Disease
Wolf, G., Chen, S., & Ziyadeh, F. N. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1626 · Cited by 565
Self-citationEvidence That the Angiotensin IV (AT4) Receptor Is the Enzyme Insulin-regulated Aminopeptidase
Albiston, A. L., McDowall, S. G., Matsacos, D., Sim, P., Clune, E., Mustafa, T., Lee, J., Mendelsohn, F. A. O., Simpson, R. J., Connolly, L. M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100512200 · Cited by 461
Huang, Y., Wongamorntham, S., Kasting, J., McQuillan, D., Owens, R. T., Yu, L., Noble, N. A., & Border, W. (2006) · Kidney International · doi:10.1038/sj.ki.5000011 · Cited by 423
Renal albumin absorption in physiology and pathology
Birn, H., & Christensen, E. I. (2006) · Kidney International · doi:10.1038/sj.ki.5000141 · Cited by 381
Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy
Tikellis, C., Johnston, C. I., Forbes, J. M., Burns, W. C., Burrell, L. M., Risvanis, J., & Cooper, M. E. (2003) · Hypertension · doi:10.1161/01.hyp.0000060689.38912.cb · Cited by 350
Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach
Lautrette, A., Li, S., Alili, R., Sunnarborg, S. W., Burtin, M., Lee, D. C., Friedlander, G., & Terzi, F. (2005) · Nature Medicine · doi:10.1038/nm1275 · Cited by 343
Cited by
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Mechanisms of Tubulointerstitial Fibrosis
Zeisberg, M., & Neilson, E. G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080793 · Cited by 868
Angiotensin II revisited: new roles in inflammation, immunology and aging
Benigni, A., Cassis, P., & Remuzzi, G. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000080 · Cited by 757
“Ang II promotes reactive oxygen species (ROS) production, cell growth, apoptosis, cell migration and differentiation, extracellular matrix remodelling, regulates gene expression and can activate multiple intracellular signalling pathways leading to tissue injury (Ruster & Wolf, 2006).”
BackgroundNguyen, H. T., Benson, C. B., Bromley, B., Campbell, J. B., Chow, J., Coleman, B., Cooper, C., Crino, J., Darge, K., Anthony Herndon, C. D., et al. (2014) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2014.10.002 · Cited by 561
“The beneficial role of angiotensin blockade in CKD is thought to stem not only from antihypertensive effect, but also by general renoprotection as a result of decreasing intraglomerular filtration pressure, proteinuria, and profibrogenic cytokines [80].”
BackgroundObesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease
Wahba, I. M., & Mak, R. H. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04071206 · Cited by 513
Chevalier, R. L. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00164.2016 · Cited by 483
Sun, C.-Y., Chang, S.-C., & Wu, M.-S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034026 · Cited by 310
Tedesco, D., & Haragsim, L. (2012) · Journal of Transplantation · doi:10.1155/2012/230386 · Cited by 302
Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease
Siragy, H. M., & Carey, R. M. (2010) · American Journal of Nephrology · doi:10.1159/000313363 · Cited by 293
Mennuni, S., Rubattu, S., Pierelli, G., Tocci, G., Fofi, C., & Volpe, M. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2013.55 · Cited by 292
Cheng, J., Zhang, W., Zhang, X., Han, F., Li, X., He, X., Li, Q., & Chen, J. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.348 · Cited by 280
Angiotensin II–Induced Reactive Oxygen Species and the Kidney
Sachse, A., & Wolf, G. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007020149 · Cited by 279
Self-citationNovel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome
Rysz, J., Gluba-Brzózka, A., Franczyk, B., Jabłonowski, Z., & Ciałkowska-Rysz, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081702 · Cited by 278
Suppression of renin–angiotensin gene expression in the kidney by paricalcitol
Freundlich, M., Quiroz, Y., Zhang, Z., Zhang, Y., Bravo, Y., Weisinger, J. R., Li, Y. C., & Rodriguez-Iturbe, B. (2008) · Kidney International · doi:10.1038/ki.2008.408 · Cited by 263
Metadata
- Authors
- Rüster, C., & Wolf, G.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2006-11
- Volume
- 17
- Issue
- 11
- Pages
- 2985-2991
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2097805169
- Cited by
- 463
- References
- 44
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.